<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJMPCERO</journal-id><journal-title-group><journal-title>International Journal of Medical Physics, Clinical Engineering and Radiation Oncology</journal-title></journal-title-group><issn pub-type="epub">2168-5436</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijmpcero.2018.74042</article-id><article-id pub-id-type="publisher-id">IJMPCERO-88363</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject></subj-group></article-categories><title-group><article-title>
 
 
  Partial and Full Arc Volumetric Modulated Arc Therapy in Lung Cancer Stereotactic Body Radiotherapy with Different Definitions of Internal Target Volume Based on 4D CT
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Didi</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ce</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiaomin</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yongqiang</surname><given-names>Zhou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Changfei</surname><given-names>Gong</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Congying</surname><given-names>Xie</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiance</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Medical Engineering Department, The 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</addr-line></aff><aff id="aff2"><addr-line>Radiation and Medical Oncology Department, The 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>09</month><year>2018</year></pub-date><volume>07</volume><issue>04</issue><fpage>491</fpage><lpage>502</lpage><history><date date-type="received"><day>5,</day>	<month>October</month>	<year>2018</year></date><date date-type="rev-recd"><day>6,</day>	<month>November</month>	<year>2018</year>	</date><date date-type="accepted"><day>9,</day>	<month>November</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Purpose: </b>
  To investigate the feasibility of partial arc volumetric modulated arc therapy (VMAT) in lung cancer stereotactic body radiotherapy (SBRT), as well the volumetric and dosimetric effects of different internal target volume (ITV) definitions with 4D CT.<b> Methods: </b>Fourteen patients with primary and metastatic lung cancer underwent SBRT were enrolled. Full and partial arc VMAT plans were generated with four different ITVs: ITV
  <sub></sub>
  <sub>all</sub>
  <sub></sub>
  , ITV
  <sub></sub>
  <sub>MIP</sub>
  <sub></sub>
  , ITV
  <sub></sub>
  <sub>AIP</sub>
  <sub></sub>
   and ITV
  <sub></sub>
  <sub>2phases</sub>
  <sub></sub>
  , representing ITVs generated from all 10 respiratory phases, maximum intensity projection (MIP), average intensity projection (AIP), and 2 extreme respiratory phases. Volumetric and dosimetric differences, as well as MU and delivery time were investigated. <b>Results: </b>Partial arc VMAT irradiated more dose at 2 cm away from planning target volume (PTV) (P
   
  =
   
  0.002), however, it achieved better protection on mean lung dose , lung V5, spinal cord, heart and esophagus compared with full arc VMAT. The average MU and delivery time of partial arc VMAT were 240 and 1.6 min less than those of full arc VMAT. There were no significant differences on target coverage and organ at risks (OARs) sparing among four ITVs. The average percent volume differences of ITV
  <sub></sub>
  <sub>MIP</sub>
  <sub></sub>
  , ITV
  <sub></sub>
  <sub>AIP</sub>
  <sub></sub>
   and ITV
  <sub></sub>
  <sub>2phases</sub>
  <sub></sub>
   to ITV
  <sub></sub>
  <sub>all</sub>
  <sub></sub>
   were 8.6%, 13.4%, and 25.2%, respectively.<b> Conclusions:</b> Although partial arc VMAT delivered more dose 2 cm out of PTV, it decreases the dose to lung, spinal cord, and esophagus, as well decreased the total MU and delivery time compared with full arc VMAT without sacrificing target coverage. Partial arc VMAT was feasible and more efficient for lung SBRT.
 
</p></abstract><kwd-group><kwd>Lung Cancer</kwd><kwd> Stereotactic Body Radiotherapy</kwd><kwd> Four Dimensional Computed Tomography</kwd><kwd> Internal Target Volume</kwd><kwd> Volumetric Modulated Arc Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Lung cancer remains the leading cause of cancer death in both men and women in the United States [<xref ref-type="bibr" rid="scirp.88363-ref1">1</xref>] , Asian countries [<xref ref-type="bibr" rid="scirp.88363-ref2">2</xref>] , and the world [<xref ref-type="bibr" rid="scirp.88363-ref3">3</xref>] . Currently, stereotactic body radiotherapy (SBRT) has been widely applied to treat patients with medically inoperable non-small-cell lung carcinoma (NSCLC) [<xref ref-type="bibr" rid="scirp.88363-ref4">4</xref>] and oligometastatic lung cancers [<xref ref-type="bibr" rid="scirp.88363-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.88363-ref6">6</xref>] . Three dimensional conformal radiation therapy (3DCRT) with 10 - 15 static fields is the most common technique used to create the desired conformal dose distribution for SBRT. The main drawback of 3DCRT planning is the lengthy treatment time relating to patient setup and radiation delivery resulted from many fields needed to create an acceptable treatment plan [<xref ref-type="bibr" rid="scirp.88363-ref7">7</xref>] . Depending on equipment and dose rate utilised, patient setup time can take up to 22 min and 100 min for treatment delivery [<xref ref-type="bibr" rid="scirp.88363-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.88363-ref9">9</xref>] . Longer treatment time significantly increases the chances of intrafraction motion and error [<xref ref-type="bibr" rid="scirp.88363-ref10">10</xref>] . Many conformal SBRT studies have reported frequently occurring and clinically significant treatment related toxicity complications [<xref ref-type="bibr" rid="scirp.88363-ref11">11</xref>] .</p><p>Recently there has been much interest in mitigating the risks associated with SBRT by delivering stereotactic doses through different techniques other than static noncoplanar/planer 3DCRT beams, such as intensity modulated therapy (IMRT) [<xref ref-type="bibr" rid="scirp.88363-ref12">12</xref>] , volumetric modulated arc therapy (VMAT) [<xref ref-type="bibr" rid="scirp.88363-ref13">13</xref>] . VMAT is an extended form of IMRT with variable dose rate, gantry speed, and dynamic multileaf collimator movement [<xref ref-type="bibr" rid="scirp.88363-ref14">14</xref>] . The capability of VMAT to increase the sparing of organs at risk (OARs) without compromising conformal dose distributions in a shorter treatment time compared with IMRT and 3DCRT has been demonstrated for both conventional fractional radiotherapy and SBRT in the treatment of lung cancer [<xref ref-type="bibr" rid="scirp.88363-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.88363-ref16">16</xref>] .</p><p>SBRT allows delivery of very high fraction dose in a few fractions, and it requires both a precise target definition with a relatively tight margin around gross tumor volume (GTV) and a careful target motion management with precise daily set-up verification prior to achieve conformal planning. An individual internal target volume (ITV) for each patient will usually generate from GTV with four dimensional computed tomography (4D CT) by considering the tumor motion induced by respiratory to achieve adequate tumor coverage and spare surrounding normal tissues [<xref ref-type="bibr" rid="scirp.88363-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.88363-ref18">18</xref>] . Ideally, the most accurate way to determine ITV is to contour GTVs in a 4D CT set with 10 breath phases, but this is very time-consuming and labor-intensive. To reduce the workload of contouring multiple GTVs, maximum intensity projection (MIP) technique [<xref ref-type="bibr" rid="scirp.88363-ref19">19</xref>] , average intensity projection (AIP) [<xref ref-type="bibr" rid="scirp.88363-ref20">20</xref>] , and contouring with reduced breath phases image sets [<xref ref-type="bibr" rid="scirp.88363-ref21">21</xref>] , have been suggested to form the ITV.</p><p>It is of interesting to investigate whether the application of 4D CT with different target delineations will benefit from partial arc VMAT treatment with an intend to further increase the treatment efficiency. The purpose of this study is to investigate the feasibility of partial arc VMAT SBRT, as well the volumetric and dosimetric differences of different 4D CT target delineations for lung cancers SBRT.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Patients and 4DCT Simulation</title><p>Patients with stage I primary NSCLC and less than two metastatic lung tumors were included in the study. Patients with more than three metastatic lung tumors and large primary unsuitable for SBRT were excluded. Eight patients with Stage 1 NSCLC and six with metastatic lung cancer treated by SBRT were enrolled. The average age of these patients was 60 years (range 45 - 81) at the time of treatment. BodyFix system (Elekta, Crawley, UK) was applied to immobilize the patients with their arms on the forehead to reduce the target motion and setup uncertainties. 4D CT images were acquired using a 16-slice Brilliance Big Bore CT scanner (Philips Healthcare, Cleveland, OH.) with Bellows system. Bellows is a deformable rubber belt that can measure lung volume changes when placed across the patient’s chest/waist to generate a breathing signal accordingly. 4D CT images were sorted into 10 respiratory phases after reconstruction with each representing 10% of the respiratory cycle. Two extreme inhale and exhale phases were 0% and 50% of the respiratory cycle.</p></sec><sec id="s2_2"><title>2.2. Target Delineation and Planning</title><p>A senior radiotherapy oncologist delineated the GTV in the 10 CT data sets with different respiratory phases. Four ITVs were generated: 1) ITV<sub>all</sub>: ITV generated by combining ten GTVs from the 10 4D CT data sets with different respiratory phases; 2) ITV<sub>MIP</sub>: ITV generated with MIP post-processing; 3) ITV<sub>AIP</sub>: ITV generated with AIP post-processing; 4) ITV<sub>2phases</sub>: combining GTVs on CTs of the peak inhale (0% phase) and exhale phases (50%). A PTV were generated by adding a uniform 3 mm margin to the ITVs.</p><p>Plans were generated on a free breathing CT with Monaco treatment planning system (TPS) (Monaco 5.1.1; Elekta, Crawley, UK). Monte Carlo algorithm was applied to optimized VMAT plans using identical objective functions and optimization parameters with a leaf motion of 0.46 cm/deg and a final arc space degree of 4. Full and partial arc VMAT plans were generated with a gantry rotational angle of 360 degree (from −179˚ to 180˚) and 180 degree (from −179˚ to 0˚), respectively. The effects of different ITV definitions on dosimetric distributions and the feasibility of partial arc VMAT in the lung cancer SBRT was investigated. The prescription dose for all these VMAT plans were 11 Gy per fraction for 5 fractions to achieve a biological equivalent dose (BED) of 115.5 Gy for an α/β of 10.</p><p>During planning optimization, following dosimetric constraints were followed according to RTOG 236 protocol: 95% volume of the PTV was covered by the prescribed dose; 99% volume of the PTV was covered by 90% prescribed isodose, parameters of conformal index (CI), defined as the ratio between the volume of 100% prescribed isodose and the PTV volume, the percent of maximum dose at 2 cm away from PTV (D<sub>2cm</sub>) to prescription dose in any direction, and the ratio of the volume of prescribed 50% isodose to the PTV volume (R50%) [<xref ref-type="bibr" rid="scirp.88363-ref22">22</xref>] . VMAT optimization physical constraints included a 0.30 cm grid, a 1% statistical uncertainty per calculation for Monte Carlo photon algorithm, a maximum number of control points per arc of 180 with a minimum segment width of 0.5 cm.</p></sec><sec id="s2_3"><title>2.3. Volumetric and Dosimetric Evaluation</title><p>ITV volumes were measured and compared with ITV<sub>all</sub> by percent volume difference (PVD), which was defined as ((Va − Vb)/Va). Dose-volume histogram (DVH) were analyzed to investigate the dosimetric differences caused by volumetric differences. The target coverage (V95), CI, D<sub>2cm</sub> and R<sub>50%</sub> were evaluated for PTV. For OAR evaluation, the mean lung dose (MLD), the percent lung volume irradiated by 5, 12, 20 Gy (V5, V12, V20), the D<sub>1cc</sub> of spinal cord, Dmean and D<sub>15cc</sub> of heart, Dmax and D<sub>5cc</sub> of esophagus were compared.</p></sec><sec id="s2_4"><title>2.4. Statistics</title><p>One way ANOVA method was applied to compare the volumetric and dosimetric results among different ITV methods presenting as mean &#177; standard deviation (SD)., The post hoc Turkey’s test was applied when an overall significant difference observed to determine the differed pair-wise comparisons. Statistical analysis was performed using SPSS 17.0. p &lt; 0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><p><xref ref-type="table" rid="table1">Table 1</xref> presents the detailed characteristics of the 14 lung cancer patients involved. There were two patients with tumor location in left middle lobe (LML), seven in right middle lobe (RML), three in right lower lobe (RLL), one in left upper lobe (LUL) and one in right upper lobe (RUL). <xref ref-type="fig" rid="fig1">Figure 1</xref> shows one typical contours of different ITV definitions for one patient. Detailed ITV volumes and PVD of these volumes to ITV<sub>all</sub> were also presented in <xref ref-type="table" rid="table1">Table 1</xref>. The average PVD of ITV<sub>MIP</sub>, ITV<sub>AIP</sub> and ITV<sub>2phases</sub> to ITV<sub>all</sub> were 8.6%, 13.4%, and 25.2%, respectively.</p><p>A typical dose distribution and DVH comparison between full arc and partial arc VMAT plans were presented in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>. <xref ref-type="table" rid="table2">Table 2</xref> shows the detailed dosimetric comparisons between full arc and partial arc VMAT plans. Full arc VMAT irradiated less dose 2 cm away from the PTV compared with</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Patient characteristics and volumetric differences for different internal target definition</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patients</th><th align="center" valign="middle" >Age (yr)</th><th align="center" valign="middle" >Gender</th><th align="center" valign="middle" >Tumor Location</th><th align="center" valign="middle" >GTV (cm<sup>3</sup>)</th><th align="center" valign="middle" >ITV<sub>all</sub> (cm<sup>3</sup>)</th><th align="center" valign="middle" >ITV<sub>MIP </sub> (cm<sup>3</sup>)</th><th align="center" valign="middle" >ITV<sub>AIP </sub> (cm<sup>3</sup>)</th><th align="center" valign="middle" >ITV<sub>2phases </sub> (cm<sup>3</sup>)</th><th align="center" valign="middle" >PVD<sub>MIP</sub></th><th align="center" valign="middle" >PVD<sub>AIP</sub></th><th align="center" valign="middle" >PVD<sub>2phase</sub></th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >LML</td><td align="center" valign="middle" >4.82</td><td align="center" valign="middle" >9.23</td><td align="center" valign="middle" >8.49</td><td align="center" valign="middle" >6.81</td><td align="center" valign="middle" >7.55</td><td align="center" valign="middle" >−0.08</td><td align="center" valign="middle" >−0.26</td><td align="center" valign="middle" >−0.18</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >4.05</td><td align="center" valign="middle" >9.61</td><td align="center" valign="middle" >8.67</td><td align="center" valign="middle" >6.49</td><td align="center" valign="middle" >4.60</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.32</td><td align="center" valign="middle" >−0.52</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >2.52</td><td align="center" valign="middle" >7.11</td><td align="center" valign="middle" >6.18</td><td align="center" valign="middle" >6.26</td><td align="center" valign="middle" >4.52</td><td align="center" valign="middle" >−0.13</td><td align="center" valign="middle" >−0.12</td><td align="center" valign="middle" >−0.36</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RLL</td><td align="center" valign="middle" >7.26</td><td align="center" valign="middle" >18.09</td><td align="center" valign="middle" >16.23</td><td align="center" valign="middle" >16.33</td><td align="center" valign="middle" >13.49</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.25</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >7.84</td><td align="center" valign="middle" >17.59</td><td align="center" valign="middle" >15.08</td><td align="center" valign="middle" >15.74</td><td align="center" valign="middle" >13.09</td><td align="center" valign="middle" >−0.14</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.26</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >7.05</td><td align="center" valign="middle" >15.01</td><td align="center" valign="middle" >14.00</td><td align="center" valign="middle" >13.48</td><td align="center" valign="middle" >11.76</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.22</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RLL</td><td align="center" valign="middle" >7.11</td><td align="center" valign="middle" >25.53</td><td align="center" valign="middle" >22.81</td><td align="center" valign="middle" >22.18</td><td align="center" valign="middle" >19.42</td><td align="center" valign="middle" >−0.11</td><td align="center" valign="middle" >−0.13</td><td align="center" valign="middle" >−0.24</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >10.91</td><td align="center" valign="middle" >23.93</td><td align="center" valign="middle" >22.63</td><td align="center" valign="middle" >20.45</td><td align="center" valign="middle" >17.79</td><td align="center" valign="middle" >−0.05</td><td align="center" valign="middle" >−0.15</td><td align="center" valign="middle" >−0.26</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >2.59</td><td align="center" valign="middle" >7.26</td><td align="center" valign="middle" >6.75</td><td align="center" valign="middle" >5.88</td><td align="center" valign="middle" >4.89</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >−0.19</td><td align="center" valign="middle" >−0.33</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >LML</td><td align="center" valign="middle" >4.11</td><td align="center" valign="middle" >13.30</td><td align="center" valign="middle" >12.61</td><td align="center" valign="middle" >11.95</td><td align="center" valign="middle" >11.23</td><td align="center" valign="middle" >−0.05</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >−0.16</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >RLL</td><td align="center" valign="middle" >4.80</td><td align="center" valign="middle" >18.46</td><td align="center" valign="middle" >16.51</td><td align="center" valign="middle" >16.85</td><td align="center" valign="middle" >14.87</td><td align="center" valign="middle" >−0.11</td><td align="center" valign="middle" >−0.09</td><td align="center" valign="middle" >−0.19</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >LUL</td><td align="center" valign="middle" >6.94</td><td align="center" valign="middle" >21.62</td><td align="center" valign="middle" >20.58</td><td align="center" valign="middle" >19.89</td><td align="center" valign="middle" >17.99</td><td align="center" valign="middle" >−0.05</td><td align="center" valign="middle" >−0.08</td><td align="center" valign="middle" >−0.17</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >female</td><td align="center" valign="middle" >RUL</td><td align="center" valign="middle" >3.71</td><td align="center" valign="middle" >9.43</td><td align="center" valign="middle" >8.76</td><td align="center" valign="middle" >8.85</td><td align="center" valign="middle" >7.77</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >−0.06</td><td align="center" valign="middle" >−0.18</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >male</td><td align="center" valign="middle" >RML</td><td align="center" valign="middle" >12.78</td><td align="center" valign="middle" >37.16</td><td align="center" valign="middle" >34.40</td><td align="center" valign="middle" >34.59</td><td align="center" valign="middle" >28.83</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >−0.22</td></tr></tbody></table></table-wrap><p>Notes: LML: left middle lobe; RML: right middle lobe; RLL: right low lobe; LUL; left upper lobe; RUL: right upper lobe; GTV: gross target volume; ITV: internal target volume; MIP: maximum intensity projection; AIP: average intensity projection; PVD: percent volume difference.</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> dosimetric differences with full arc VMAT plans for different ITV definitions</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >ITV<sub>all</sub></th><th align="center" valign="middle" >TIV<sub>MIP</sub></th><th align="center" valign="middle" >ITV<sub>AIP</sub></th><th align="center" valign="middle" >ITV<sub>2phase</sub></th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >PTV</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >D<sub>2cm</sub> (%)</td><td align="center" valign="middle" >59.83 &#177; 7.47</td><td align="center" valign="middle" >58.28 &#177; 5.51</td><td align="center" valign="middle" >58.00 &#177; 5.46</td><td align="center" valign="middle" >59.36 &#177; 6.43</td><td align="center" valign="middle" >0.85</td></tr><tr><td align="center" valign="middle" >CI</td><td align="center" valign="middle" >1.13 &#177; 0.06</td><td align="center" valign="middle" >1.16 &#177; 0.06</td><td align="center" valign="middle" >1.16 &#177; 0.08</td><td align="center" valign="middle" >1.17 &#177; 0.09</td><td align="center" valign="middle" >0.59</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >R<sub>50%</sub></th><th align="center" valign="middle" >5.23 &#177; 0.42</th><th align="center" valign="middle" >5.23 &#177; 0.33</th><th align="center" valign="middle" >5.30 &#177; 0.38</th><th align="center" valign="middle" >5.40 &#177; 0.38</th><th align="center" valign="middle" >0.59</th></tr></thead><tr><td align="center" valign="middle" >V<sub>95</sub> (%)</td><td align="center" valign="middle" >99.45 &#177; 0.41</td><td align="center" valign="middle" >99.48 &#177; 0.40</td><td align="center" valign="middle" >99.42 &#177; 0.53</td><td align="center" valign="middle" >99.33 &#177; 0.38</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >Lung</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MLD (cGy)</td><td align="center" valign="middle" >478.92 &#177; 98.08</td><td align="center" valign="middle" >449.07 &#177; 94.49</td><td align="center" valign="middle" >444.50 &#177; 105.04</td><td align="center" valign="middle" >424.25 &#177; 97.67</td><td align="center" valign="middle" >0.54</td></tr><tr><td align="center" valign="middle" >V5 (%)</td><td align="center" valign="middle" >23.22 &#177; 4.90</td><td align="center" valign="middle" >21.14 &#177; 4.57</td><td align="center" valign="middle" >21.60 &#177; 5.43</td><td align="center" valign="middle" >20.38 &#177; 4.68</td><td align="center" valign="middle" >0.48</td></tr><tr><td align="center" valign="middle" >V12 (%)</td><td align="center" valign="middle" >10.80 &#177; 2.99</td><td align="center" valign="middle" >10.01 &#177; 2.74</td><td align="center" valign="middle" >9.88 &#177; 2.82</td><td align="center" valign="middle" >9.23 &#177; 2.51</td><td align="center" valign="middle" >0.52</td></tr><tr><td align="center" valign="middle" >V20 (%)</td><td align="center" valign="middle" >6.48 &#177; 1.87</td><td align="center" valign="middle" >5.84 &#177; 1.61</td><td align="center" valign="middle" >5.70 &#177; 1.60</td><td align="center" valign="middle" >5.42 &#177; 1.75</td><td align="center" valign="middle" >0.42</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Spinal cord</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >D<sub>1</sub> (cGy)</td><td align="center" valign="middle" >1286.79 &#177; 343.82</td><td align="center" valign="middle" >1346.50 &#177; 349.61</td><td align="center" valign="middle" >1321.21 &#177; 390.59</td><td align="center" valign="middle" >1254.21 &#177; 443.65</td><td align="center" valign="middle" >0.93</td></tr><tr><td align="center" valign="middle" >Heart</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Dmean (cGy)</td><td align="center" valign="middle" >312.30 &#177; 202.47</td><td align="center" valign="middle" >289.68 &#177; 198.89</td><td align="center" valign="middle" >291.04 &#177; 210.27</td><td align="center" valign="middle" >259.11 &#177; 171.31</td><td align="center" valign="middle" >0.91</td></tr><tr><td align="center" valign="middle" >D<sub>15cc</sub> (cGy)</td><td align="center" valign="middle" >1290.21 &#177; 799.96</td><td align="center" valign="middle" >1225.43 &#177; 800.22</td><td align="center" valign="middle" >1266.9 &#177; 883.39</td><td align="center" valign="middle" >1033.57 &#177; 687.49</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Esophagus</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Dmax (cGy)</td><td align="center" valign="middle" >1246.86 &#177; 505.03</td><td align="center" valign="middle" >1319.07 &#177; 466.58</td><td align="center" valign="middle" >2098.64 &#177; 1653.93</td><td align="center" valign="middle" >1210.29 &#177; 422.03</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >D<sub>5cc</sub> (cGy)</td><td align="center" valign="middle" >740.04 &#177; 408.64</td><td align="center" valign="middle" >747.21 &#177; 416.30</td><td align="center" valign="middle" >738.50 &#177; 318.21</td><td align="center" valign="middle" >646.64 &#177; 301.18</td><td align="center" valign="middle" >0.87</td></tr></tbody></table></table-wrap></table-wrap-group><p>Notes: PTV: planning target volume; ITV: internal target volume; MIP: maximum intensity projection; AIP: average intensity projection; MLD: mean lung dose.</p><p>partial arc VMAT (P = 0.002). However, partial arc VMAT irradiated less MLD and V5 compared with full arc VMAT. Partial arc VMAT also achieved better protection on spinal cord, heart and esophagus compared with full arc VMAT. The average MU and delivery time of full arc VMAT plans were 240 and 1.6 min more than those of partial arc VMAT. No other significant difference was observed between these two planning schemes.</p><p>The dosimetric variations resulting from different ITVs according to full arc VMAT plans were presented in <xref ref-type="table" rid="table3">Table 3</xref>. The CI of ITV<sub>all</sub>, ITV<sub>MIP</sub>, ITV<sub>AIP</sub> and ITV<sub>2phases</sub> were 1.13 &#177; 0.06, 1.16 &#177; 0.06, 1.16 &#177; 0.08 and 1.17 &#177; 0.09, respectively. The R<sub>50%</sub> of ITV<sub>all</sub>, ITV<sub>MIP</sub>, ITV<sub>AIP</sub> and ITV<sub>2phases</sub> were 5.23 &#177; 0.42, 5.23 &#177; 0.33, 5.30 &#177; 0.38, and 5.40 &#177; 0.38, respectively. The target coverage were more than 99% for all four PTVs and no significant difference on PTV coverage was observed. There were also no significant differences on OARs sparing among these four ITVs. VMAT plans for ITV<sub>MIP</sub>, ITV<sub>AIP</sub> and ITV<sub>2phases</sub> irradiated less lung volume compared to those for ITV<sub>all</sub>, but the differences were not statistically significant. Except for ITV<sub>AIP</sub> irradiated a significant higher maximum dose to esophagus compared with plans for other three, there were no significant differences among these four ITVs on sparing of spinal cord, heart and esophagus.</p></sec><sec id="s4"><title>4. Discussion</title><p>Tumor motion caused by respiration and the effects on treatment delivering and target definition were major concerns in lung cancer SBRT. The feasibility of partial arc VMAT in lung cancer SBRT treatment, as well the volume changes</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Dosimetric comparison between full arc and partial arc VMAT plans</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Full arc VMAT</th><th align="center" valign="middle" >Partial arc VMAT</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >PTV</td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >D<sub>2cm</sub> (%)</td><td align="center" valign="middle"  colspan="2"  >58.87 &#177; 6.14</td><td align="center" valign="middle" >61.16 &#177; 6.67</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >CI</td><td align="center" valign="middle"  colspan="2"  >1.15 &#177; 0.07</td><td align="center" valign="middle" >1.14 &#177; 0.08</td><td align="center" valign="middle" >0.13</td></tr><tr><td align="center" valign="middle" >R<sub>50%</sub></td><td align="center" valign="middle"  colspan="2"  >5.29 &#177; 0.37</td><td align="center" valign="middle" >5.28 &#177; 0.37</td><td align="center" valign="middle" >0.44</td></tr><tr><td align="center" valign="middle" >V95 (%)</td><td align="center" valign="middle"  colspan="2"  >99.42 &#177; 0.42</td><td align="center" valign="middle" >99.46 &#177; 0.40</td><td align="center" valign="middle" >0.46</td></tr><tr><td align="center" valign="middle" >Lung</td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MLD (cGy)</td><td align="center" valign="middle"  colspan="2"  >449.19 &#177; 98.16</td><td align="center" valign="middle" >430.60 &#177; 99.30</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >V5 (%)</td><td align="center" valign="middle"  colspan="2"  >21.59 &#177; 4.88</td><td align="center" valign="middle" >18.50 &#177; 4.99</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >V12 (%)</td><td align="center" valign="middle"  colspan="2"  >9.98 &#177; 2.75</td><td align="center" valign="middle" >9.88 &#177; 2.73</td><td align="center" valign="middle" >0.59</td></tr><tr><td align="center" valign="middle" >V20 (%)</td><td align="center" valign="middle"  colspan="2"  >5.86 &#177; 1.71</td><td align="center" valign="middle" >5.89 &#177; 1.60</td><td align="center" valign="middle" >0.72</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Spinal cord</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >D<sub>1</sub> (cGy)</td><td align="center" valign="middle" >1302.18 &#177; 375.03</td><td align="center" valign="middle" >1043.32 &#177; 488.18</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Heart</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Dmean (cGy)</td><td align="center" valign="middle" >288.03 &#177; 191.81</td><td align="center" valign="middle" >239.50 &#177; 174.12</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >D<sub>15cc</sub> (cGy)</td><td align="center" valign="middle" >1204.04 &#177; 780.51</td><td align="center" valign="middle" >1064.21 &#177; 781.51</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Esophagus</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Dmax (cGy)</td><td align="center" valign="middle" >1468.71 &#177; 967.80</td><td align="center" valign="middle" >1115.36 &#177; 479.74</td><td align="center" valign="middle" >0.006</td></tr><tr><td align="center" valign="middle"  colspan="2"  >D<sub>5cc</sub> (cGy)</td><td align="center" valign="middle" >718.10 &#177; 357.14</td><td align="center" valign="middle" >630.89 &#177; 268.58</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>and dosimetric variation of different ITVs with 4D CT were investigated in this study.</p><p>The long delivery time required by 3DCRT SBRT is a crucial drawback due to significant changes in tumor volume and/or position resulted from respiratory motion for lung cancer patients [<xref ref-type="bibr" rid="scirp.88363-ref23">23</xref>] . Single arc VMAT planning had been reported to reduce the treatment time by 37% - 63% and reduce substantially the dose to surrounding normal tissue without comprise the target coverage compared to 3DCRT [<xref ref-type="bibr" rid="scirp.88363-ref24">24</xref>] . In this study, partial arc VMAT was applied to further reduce the required MU and treatment time.</p><p>As shown in <xref ref-type="table" rid="table2">Table 2</xref>, there was no significantly difference between full arc and partial arc VMAT in target coverage except for that partial arc VMAT irradiated more dose at 2 cm away from the PTV (P = 0.002). As for normal tissue sparing, partial arc VMAT irradiated less MLD, V5, and achieved better protection on spinal cord, heart and esophagus compared with full arc VMAT. Although the magnitudes of these reductions were small, partial arc VMAT decreased the average MU by 240 and the treatment time by 1.6 min compared with full arc VMAT. This improved treatment efficiency will reduce the patient’s time on the table and lead to enhance patient satisfaction and comfort, reduce intrafraction variation, increase time for image-guided positioning and correction, and potentially lead to further reduction in target margin requirements [<xref ref-type="bibr" rid="scirp.88363-ref25">25</xref>] .</p><p>Target motion of lung cancer caused by respiration is often unpredictable and a generous isocentric expansion of GTV based on 3D CT images is usually can not fully cover it [<xref ref-type="bibr" rid="scirp.88363-ref26">26</xref>] . Individualized target volume including tumor motion is believed achievable with 4D CT. However, it is still uncertain how can we utilize the information of 4D CT best to generate ITV [<xref ref-type="bibr" rid="scirp.88363-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.88363-ref28">28</xref>] . In this study, the average PVD of ITV<sub>MIP</sub>, ITV<sub>AIP</sub> and ITV<sub>2phases</sub> to ITV<sub>all</sub> were 8.6%, 13.4%, and 25.2%, respectively. The MIP-based ITVs showed best agreement with ITV<sub>all</sub>. This was consistent with previous studies in which it reported that MIP-based ITV was widely adapted due to its excellent correlation with ITV<sub>all</sub> and significantly reduced clinical workload associated with treatment planning [<xref ref-type="bibr" rid="scirp.88363-ref23">23</xref>] .</p><p>MIP projections reflect the highest data value encountered along the viewing ray for each pixel of volumetric data, giving rise to a full intensity display of the brightest object along each ray on the projection image. As such, these projections represent composite images with phase summation of tumor positions during all phases of respiration, thereby allowing for direct generation of ITVs. However, when a tumor was located adjacent to high intensity tissues, MIP images may fail to visualize the full extent of the ITV<sub>all</sub> as a result of ITV<sub>all</sub> overlapping with tissues due to respiratory motion, leading to significant underestimation of ITV<sub>all</sub> by ITV<sub>MIP</sub> [<xref ref-type="bibr" rid="scirp.88363-ref29">29</xref>] . The small PVD between ITV<sub>all</sub> and ITV<sub>MIP</sub> in this study may partially due to contour deviations and due to the vicinity of some tumor location to lower and upper lobes.</p><p>The ITV<sub>AIP</sub> and ITV<sub>2phases</sub> were much less than those of ITV<sub>all</sub>. The ITV<sub>2phases</sub> in this study was nearly 25% less than ITV<sub>all</sub>. This is not a minor deviation considered the small tumor volume of SBRT lung patients as declared in other study [<xref ref-type="bibr" rid="scirp.88363-ref30">30</xref>] . A percent volume difference of 15.3% &#177; 6.6% between ITV<sub>2phases</sub> and ITV<sub>all</sub> had also been reported [<xref ref-type="bibr" rid="scirp.88363-ref31">31</xref>] . However, these volumetric differences did not result in significant dosimetric deviations.</p><p>As shown in <xref ref-type="table" rid="table2">Table 2</xref>, the dose differences were small among different ITVs. No significant difference on CI and target coverage was observed. The MLD and the percent lung volume irradiated by certain dose of ITV<sub>2phases</sub> were smaller than those of ITV<sub>all</sub> resulted from the significant volumetric differences. The doses delivered to the normal tissues were similar among ITV<sub>all</sub>, ITV<sub>MIP</sub> and ITV<sub>AIP</sub>. Contrary, a previous study reported significant decreases in MLD, lung percent volumes with the decrease of ITV volumes [<xref ref-type="bibr" rid="scirp.88363-ref30">30</xref>] . This inconsistency could be resulted from different normal lung delineations and different window/level settings were applied.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Although partial arc VMAT delivered more dose 2 cm out of PTV, it decreases the dose to lung, spinal cord, and esophagus compared with full arc VMAT without sacrificing target coverage. Partial arc VMAT also decreased the total MU and delivery time. Although ITV volumes based on MIP, AIP and 2 extreme phases of 4D CT were smaller than ITV generated from all ten respiratory phases, there were no significant dosimetric differences resulted due to a relative small GTV of lung SBRT patients.</p></sec><sec id="s6"><title>Acknowledgements</title><p>The study was partially supported by a grant from National Natural Science Foundation of China (11675122), Natural Science Foundation of Zhejiang Province (Y17H160199), and Health Science Technology Funding of Zhejiang Provincial Health Department (2015KYB241).</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><sec id="s8"><title>Cite this paper</title><p>Wang, W., Chen, D.D., Han, C., Zheng, X.M., Zhou, Y.Q., Gong, C.F., Xie, C.Y. and Jin, X.C. (2018) Partial and Full Arc Volumetric Modulated Arc Therapy in Lung Cancer Stereotactic Body Radiotherapy with Different Definitions of Internal Target Volume Based on 4D CT. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 7, 491-502. https://doi.org/10.4236/ijmpcero.2018.74042</p></sec><sec id="s9"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.88363-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer Statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249. https://doi.org/10.3322/caac.20006</mixed-citation></ref><ref id="scirp.88363-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yang, B.H., Parkin, D.M., Cai, L. and Zhang, Z.F. (2004) Cancer Burden and Trends in the Asian Pacific Rim Region. Asian Pacific Journal of Cancer Prevention, 5, 96-117.</mixed-citation></ref><ref id="scirp.88363-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pisani, P., Parkin, D.M. and Ferlay, J. (1993) Estimates of the Worldwide Mortality from Eighteen Major Cancers in 1985. Implications for Prevention and Projections of Future Burden. International Journal of Cancer, 55, 891-903. https://doi.org/10.1002/ijc.2910550604</mixed-citation></ref><ref id="scirp.88363-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ettinger, D.S., Wood, D.E., Akerley, W., Bazhenova, L.A., Borghaei, H., Camidge, D.R., et al. (2014) Non-Small Cell Lung Cancer, Version 1.2015. Journal of the National Comprehensive Cancer Network, 12, 1738-1761. https://doi.org/10.6004/jnccn.2014.0176</mixed-citation></ref><ref id="scirp.88363-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Takeda, A., Kunieda, E., Ohashi, T., Aoki, Y., Koike, N. and Takeda, T. (2011) Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Tumors from Colorectal Cancer and Other Primary Cancers in Comparison with Primary Lung Cancer. Radiotherapy &amp; Oncology, 101, 255-259. https://doi.org/10.1016/j.radonc.2011.05.033</mixed-citation></ref><ref id="scirp.88363-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Norihisa, Y., Nagata, Y., Takayama, K., Matsuo, Y., Sakamoto, T., Sakamoto, M., et al. (2008) Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors. International Journal of Radiation Oncology-Biology-Physics, 72, 398-403. https://doi.org/10.1016/j.ijrobp.2008.01.002</mixed-citation></ref><ref id="scirp.88363-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Benedict, S.H., Yenice, K.M., Followill, D., Galvin, J.M., Hinson, W., Kavanagh, B., et al. (2010) Stereotactic Body Radiation Therapy: The Report of AAMP Task Group 101. Medical Physics, 37, 4078-4101. https://doi.org/10.1118/1.3438081</mixed-citation></ref><ref id="scirp.88363-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hodge, W., Tomé, W.A., Jaradat, H.A., Orton, N.P., Khuntia, D., Traynor, A., et al. (2006) Feasibility Report of Image Guided Stereotactic Body Radiotherapy (IG-SBRT) with Tomotherapy for Early Stage Medically Inoperable Lung Cancer Using Extreme Hypofractionation. Acta Oncologica, 45, 890-896. https://doi.org/10.1080/02841860600907329</mixed-citation></ref><ref id="scirp.88363-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">van der Voort van Zyp, N.C., van der Holt, B., van Klaveren, R.J., Pattynama, P., Maat, A. and Nuyttens, J.J. (2010) Stereotactic Body Radiotherapy Using Real-Time Tumor Tracking in Octogenarians with Non-Small Cell Lung Cancer. Lung Cancer, 69, 296-301. https://doi.org/10.1016/j.lungcan.2009.12.008</mixed-citation></ref><ref id="scirp.88363-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hoogeman, M.S., Nuyttens, J.J., Levendag, P.C. and Heijmen, B.J. (2008) Time Dependence of Intrafraction Patient Motion Assessed by Repeat Stereoscopic Imaging. International Journal of Radiation Oncology-Biology-Physics, 70, 609-618. https://doi.org/10.1016/j.ijrobp.2007.08.066</mixed-citation></ref><ref id="scirp.88363-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lo, S.S., Sahgal, A., Chang, E.L., Mayr, N.A., The, B.S., Huang, Z., et al. (2013) Serious Complications Associated with Stereotactic Ablative Radiotherapy and Strategies to Mitigate the Risk. Journal of Clinical Oncology, 25, 378-387. https://doi.org/10.1016/j.clon.2013.01.003</mixed-citation></ref><ref id="scirp.88363-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kang, H., Yorke, E., Yang, J., Chui, C., Rosenzweig, K. and Amols, H. (2010) Evaluation of Tumor Motion Effects on Dose Distribution for Hypofractionated Intensity-Modulated Radiotherapy of Non-Small Cell Lung Cancer. Journal of Applied Clinical Medical Physics, 11, 3182. https://doi.org/10.1120/jacmp.v11i3.3182</mixed-citation></ref><ref id="scirp.88363-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ong, C.L., Verbakel, W.F.A.R., Dahele, M., Cuijpers, J.P., Slotman, B.J. and Senan, S. (2012) Fast Arc Delivery for Stereotactic Body Radiotherapy of Vertebral and Lung Tumors. International Journal of Radiation Oncology-Biology-Physics, 83, e137-143. https://doi.org/10.1016/j.ijrobp.2011.12.014</mixed-citation></ref><ref id="scirp.88363-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Otto, K. (2008) Volumetric Modulated Arc Therapy: IMRT in a Single Gantry Arc. Medical Physics, 35, 310-317. https://doi.org/10.1118/1.2818738</mixed-citation></ref><ref id="scirp.88363-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Rauschenbach, B.M., Mackowiak, L. and Malhotra, H.K. (2014) A Dosimetric Comparison of Three-Dimensional Conformal Radiotherapy, Volumetric-Modulated Arc Therapy, and Dynamic Conformal Arc Therapy in the Treatment of Non-Small Cell Lung Cancer Using Stereotactic Body Radiotherapy. Journal of Applied Clinical Medical Physics, 15, 147-161. https://doi.org/10.1120/jacmp.v15i5.4898</mixed-citation></ref><ref id="scirp.88363-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ong, C.L., Verbakel, W.F., Cuijpers, J.P., Slotman, B.J., Lagerwaard, F.J. and Senan, S. (2010) Stereotactic Radiotherapy for Peripheral Lung Tumors: A Comparison of Volumetric Modulated Arc Therapy with 3 Other Delivery Techniques. Radiation Oncology, 97, 437-442. https://doi.org/10.1016/j.radonc.2010.09.027</mixed-citation></ref><ref id="scirp.88363-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Liu, H.H., Balter, P., Tutt, T., Choi, B., Zhang, J., Wang, C., et al. (2007) Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer. International Journal of Radiation Oncology-Biology-Physics, 68, 531-540. https://doi.org/10.1016/j.ijrobp.2006.12.066</mixed-citation></ref><ref id="scirp.88363-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Jin, J.Y., Ajlouni, M., Chen, Q., Yin, F.F. and Movsas, B. (2006) A TEchnique of Using Gated-CT Images to Determine Internal Target Volume (ITV) for Fractionated Stereotactic Lung Radiotherapy. Radiation Oncology, 78, 177-184. https://doi.org/10.1016/j.radonc.2005.11.012</mixed-citation></ref><ref id="scirp.88363-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ezhil, M., Vedam, S., Balter, P., Choi, B., Mirkovic, D., Starkschall, G., et al. (2009) Determination of Patient-Specific Internal Gross Tumor Volumes for Lung Cancer Using Four-Dimensional Computed Tomography. Radiation Oncology, 27, 4. https://doi.org/10.1186/1748-717X-4-4</mixed-citation></ref><ref id="scirp.88363-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ehler, E.D. and Tomé, W.A. (2008) Lung 4D-IMRT Treatment Planning: An Evaluation of Three Methods Applied to Four-Dimensional Data Sets. Radiation Oncology, 88, 319-325. https://doi.org/10.1016/j.radonc.2008.07.004</mixed-citation></ref><ref id="scirp.88363-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Rosu, M., Balter, J.M., Chetty, I.J., Kessler, M.L., McShan, D.L., Balter, P., et al. (2007) How Extensive of a 4D Dataset Is Needed to Estimate Cumulative Dose Distribution Plan Evaluation Metrics in Conformal Lung Therapy? Medical Physics, 34, 233-245. https://doi.org/10.1118/1.2400624</mixed-citation></ref><ref id="scirp.88363-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Michalski, J., Timmerman, R., Fowler, J., Cho, H., Johnston, D., Galvin, J.M., et al. (2009) A Phase II Trial of SBRT in the Treatment of Patients with Medically Inoperable Stage I/II NSCLC. RTOG 0236. RTOG, 1-39.</mixed-citation></ref><ref id="scirp.88363-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Underberg, R.W., Lagerwaard, F.J., van Tinteren, H., Cuijpers, J.P., Slotman, B.J. and Senan, S. (2006) Time Trends in Target Volumes for Stage I Non-Small-Cell Lung Cancer after Stereotatctic Radiotherapy. International Journal of Radiation Oncology-Biology-Physics, 64, 1221-1228. https://doi.org/10.1016/j.ijrobp.2005.09.045</mixed-citation></ref><ref id="scirp.88363-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">McGrath, S.D., Matuszak, M.M., Yan, D., Kestin, L.L., Martinez, A.A. and Grills, I.S. (2010) Volumetric Modulated Arc Therapy for Delivery of Hypofractionated Stereotactic Lung Radiotherapy: A Dosimetric and Treatment Efficiency Analysis. Radiation Oncology, 95, 153-157. https://doi.org/10.1016/j.radonc.2009.12.039</mixed-citation></ref><ref id="scirp.88363-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Grills, I.S., Hugo, G., Kestin, L.L., Galerani, A.P., Chao, K.K., Wloch, J., et al. (2008) Image-Guided Radiotherapy via Daily Online Cone-Beam CT Substantially Reduces Margin Requirements for Stereotactic Lung Radiotherapy. International Journal of Radiation Oncology-Biology-Physics, 70, 1045-1056. https://doi.org/10.1016/j.ijrobp.2007.07.2352</mixed-citation></ref><ref id="scirp.88363-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Rietzel, E., Liu, A.K., Chen, G.T. and Choi, N.C. (2008) Maximum-Intensity Volumes for Fast Contouring of Lung Tumors Including Respiratory Motion in 4DCT Planning. International Journal of Radiation Oncology-Biology-Physics, 71, 1245-1252. https://doi.org/10.1016/j.ijrobp.2008.03.030</mixed-citation></ref><ref id="scirp.88363-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">van Dam, I.E., van S&amp;#246;rnsen de Koste, J.R., Hanna, G.G., Muirhead, R., Slotman, B.J. and Senan, S. (2010) Improving Target Delineation on 4-Dimensional CT Scans in Stage I NSCLC Using a Deformable Registration Tool. Radiation Oncology, 96, 67-72. https://doi.org/10.1016/j.radonc.2010.05.003</mixed-citation></ref><ref id="scirp.88363-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, B., Yang, Y., Li, T., Li, X., Heron, D.E. and Huq, M.S. (2009) Image-Guided Respiratory-Gated Lung Stereotactic Body Radiotherapy: Which Target Definition Is Optimal. Medical Physics, 36, 2248-2257. https://doi.org/10.1118/1.3129161</mixed-citation></ref><ref id="scirp.88363-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Muirhead, R., McNee, S.G., Featherstone, C., Moore, K. and Muscat, S. (2008) Use of Maximum Intensity Projections (MIPs) for Target Outlining in 4DCT Radiotherapy Planning. Journal of Thoracic Oncology, 3, 1433-1438. https://doi.org/10.1097/JTO.0b013e31818e5db7</mixed-citation></ref><ref id="scirp.88363-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Yeo, S.G. and Kim, E.S. (2013) Efficient Approach for Determining Four-Dimensional Computed Tomography-Based Internal Target Volume in Stereotactic Radiotherapy of Lung Cancer. Radiation Oncology Journal, 31, 247-251. https://doi.org/10.3857/roj.2013.31.4.247</mixed-citation></ref><ref id="scirp.88363-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Jang, S.S., Huh, G.J., Park, S.Y., Yang, P.S., Chung, H.N., Seo, J.H., Park, J.C., et al. (2014) Reconstitution of Internal Target Volumes by Combining Four-Dimensional Computed Tomography and a Modified Slow Computed Tomography Scan in Stereotactic Body Radiotherapy Planning for Lung Cancer. Radiation Oncology, 9, 106. https://doi.org/10.1186/1748-717X-9-106</mixed-citation></ref></ref-list></back></article>